Trends & Treatment Insights for 2025 Real-world data show rapid adoption in type 2 diabetes care: between early 2022 and mid-2024, roughly 1 in 5 type 2 diabetes patients were on GLP-1 therapy
[11] In other words, people engaging in this experiment are doing so without the guidance of any researchit is essentially uncharted territory
(a-c): data represented as mean +/- SEM
GLP-1 therapy has no contraindication with Botox, microneedling, facials, or other aesthetic treatments at TOCC Aesthetics
Effects and mechanisms of luteolin, a plant-based flavonoid, in the prevention of cancers via modulation of inflammation and cell signaling molecules
Ten years ago, I wouldve been more anxious